News Breaks |
|
|
| February 19, 2013 |
| 05:41 EDT |  | REGN | Regeneron, Bayer start Phase 3 trial of Eylea in Asia, Russia
Regeneron Pharmaceuticals and Bayer HealthCare announced that they have initiated a new Phase 3 trial to evaluate the efficacy and safety of Eylea Injection in the treatment of Diabetic Macular Edema, or in Russia, China, and other Asian countries. The companies are extending their global development program for Eylea in DME after promising results in the global Phase 2 DME program. |
|
|
News For REGN From The Last 14 Days Check below for free stories on REGN the last two weeks. |
|
|
| May 20, 2013 |
| 07:28 EDT |  | REGN | American Thoracic Society to hold a conference
 Subscribe for More Information |
|
| May 17, 2013 |
| 10:07 EDT |  | REGN | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| 07:16 EDT | | REGN | Regeneron initiated with a Neutral at UBS
Subscribe for More Information |
|
| 06:33 EDT | | REGN | American Thoracic Society to hold a conference
Subscribe for More Information |
|
| May 15, 2013 |
| 05:39 EDT | | REGN | Sanofi, Regeneron announce patient enrollment in two Phase 3 trials
Subscribe for More Information |
|
| May 14, 2013 |
| 07:34 EDT |  | REGN | Regeneron outlook positive, says RBC Capital
Subscribe for More Information |
|
| May 10, 2013 |
| 07:24 EDT | | REGN | Credit Suisse to host a conference
Subscribe for More Information |
|
| May 6, 2013 |
| 09:02 EDT | | REGN | Regeneron price target raised to $314 from $200 at Roth Capital
Subscribe for More Information |
|
|
|
|
|
